Chronic Kidney Disease Management

Introduction to CKD Management

• The primary goals of chronic kidney disease (CKD) management are to delay disease progression, prevent complications, reduce cardiovascular risk, and improve quality of life through a comprehensive treatment strategy that includes lifestyle modifications, pharmacotherapy, and appropriate renal replacement therapy when needed, as recommended by the Kidney International guidelines 1, 2

Goals of CKD Management

• Delay progression of kidney disease through targeted interventions, as suggested by the Kidney International guidelines 2, 1
• Manage CKD-specific complications (anemia, metabolic bone disease, acidosis) to improve patient outcomes, according to the Diabetes Care and Kidney International guidelines 2, 3
• Reduce cardiovascular risk, which is significantly elevated in CKD patients, as recommended by the Kidney International guidelines 1, 4

Lifestyle Modifications for CKD Management

• Optimize physical activity and weight management to improve overall health outcomes, as suggested by the Kidney International guidelines 1, 4
• Implement healthy dietary patterns, with consideration for plant-based diets when appropriate, to slow disease progression, as recommended by the Kidney International guidelines 1
• Maintain protein intake at 0.8 g/kg body weight per day for non-dialysis CKD patients to avoid high protein intake (>1.3 g/kg/day) which can accelerate kidney function decline, according to the Diabetes Care guidelines 3
• Restrict dietary sodium to <2,300 mg/day to control blood pressure and reduce cardiovascular risk, as recommended by the Diabetes Care guidelines 3

Pharmacological Interventions for CKD Management

• SGLT2 inhibitors should be first-line therapy for most CKD patients to slow disease progression, regardless of diabetes status, as recommended by the Kidney International guidelines 1
• Renin-angiotensin system (RAS) inhibitors (ACE inhibitors or ARBs) at maximum tolerated doses for patients with hypertension, particularly those with albuminuria, to reduce cardiovascular risk, as suggested by the Kidney International guidelines 1
• Blood pressure control with a target systolic BP <120 mmHg to reduce risk of CKD progression, as recommended by the Kidney International and Diabetes Care guidelines 1, 5
• Statin therapy for cardiovascular risk reduction in CKD patients, as recommended by the Kidney International and Diabetes Care guidelines 1, 5

Management of CKD Complications

• Monitor hemoglobin regularly; treatment is indicated when hemoglobin falls below target levels to manage anemia, as suggested by the Diabetes Care guidelines 5, 3
• Iron supplementation should be considered before or in conjunction with erythropoiesis-stimulating agents to manage anemia, according to the Diabetes Care guidelines 3
• Monitor serum bicarbonate levels regularly to manage metabolic acidosis, as recommended by the Diabetes Care guidelines 5, 3
• Treat metabolic acidosis with oral alkali supplementation to maintain serum bicarbonate within normal range, as suggested by the Diabetes Care guidelines 3
• Monitor serum potassium, especially in patients on RAS inhibitors, diuretics, or MRAs, to manage electrolyte abnormalities, as recommended by the Diabetes Care guidelines 5, 3
• Individualize dietary potassium restrictions based on serum levels to manage electrolyte abnormalities, according to the Diabetes Care guidelines 3

Renal Replacement Therapy for End-Stage Renal Disease (ESRD)

• Timely planning for kidney replacement therapy is essential for optimal outcomes, as recommended by the Kidney International guidelines 2

Integrated Care Approach for CKD Management

• Implement a team approach with nephrologists, primary care providers, dietitians, pharmacists, and other specialists to provide comprehensive care, as suggested by the Kidney International guidelines 2
• Regular risk factor reassessment every 3-6 months to monitor disease progression, as recommended by the Kidney International guidelines 1
• Prioritize patient concerns, values, and preferences in treatment decisions to improve patient outcomes, according to the Kidney International guidelines 2
• Provide comprehensive medication management, including dose adjustments for kidney function, medication reconciliation, and deprescribing when appropriate, as recommended by the Kidney International guidelines 2

Common Pitfalls to Avoid in CKD Management

• Delaying nephrology referral for advanced CKD (eGFR <30 mL/min/1.73m²) can lead to poor outcomes, as suggested by the Kidney International guidelines 2
• Overlooking the importance of lifestyle modifications alongside pharmacotherapy can lead to poor outcomes, according to the Kidney International guidelines 1
• Failure to prepare patients for renal replacement therapy in a timely manner can lead to poor outcomes, as recommended by the Kidney International guidelines 2
• Neglecting to screen for and manage CKD complications until they become severe can lead to poor outcomes, according to the Diabetes Care guidelines 5

Comprehensive Management of Chronic Kidney Disease

Introduction to CKD Management

• The American College of Cardiology recommends that all CKD patients receive SGLT2 inhibitors as foundational first-line therapy combined with RAS inhibition (ACE inhibitor or ARB) when hypertension or albuminuria is present, plus statin therapy, forming the core triad of kidney and cardiovascular protection 6, 7, 8

First-Line Pharmacological Therapy

• Initiate SGLT2 inhibitors immediately when eGFR ≥20 mL/min/1.73 m² and continue until dialysis or transplantation, as recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) guideline 6, 8
• Continue SGLT2 inhibitors even as eGFR declines below 20 mL/min/1.73 m² until dialysis initiation, according to the National Kidney Foundation (NKF) 6, 8
• RAS inhibition (ACE inhibitors or ARBs) is mandatory when albuminuria is present and first-line when hypertension exists, as stated by the American Heart Association (AHA) 6, 7, 8
• Titrate RAS inhibitors to maximum tolerated dose for optimal kidney and cardiovascular protection, as recommended by the European Society of Cardiology (ESC) 6

Blood Pressure Management

• Target systolic BP <120 mmHg for most CKD patients to reduce progression risk, according to the American College of Cardiology (ACC) 6, 8
• When albuminuria is present, ACE inhibitors or ARBs must be the first-line agent, as stated by the Kidney Disease: Improving Global Outcomes (KDIGO) guideline 6, 8

Advanced Kidney and Heart Protection

• Nonsteroidal mineralocorticoid receptor antagonists, such as finerenone, provide additive kidney and cardiovascular protection beyond SGLT2 inhibitors and RAS blockade, as recommended by the European Society of Cardiology (ESC) 6, 8

Lipid Management

• All adults ≥50 years with eGFR <60 mL/min/1.73 m² require statin or statin/ezetimibe combination, according to the American College of Cardiology (ACC) 7, 8
• Add ezetimibe 10 mg daily if LDL targets are not met or if there is a high ASCVD risk, as recommended by the National Lipid Association (NLA) 6, 7, 8

Cardiovascular Disease Management

• Aspirin 81 mg daily is recommended for secondary prevention in established cardiovascular disease (lifelong) and considered for primary prevention in high ASCVD risk patients, according to the American Heart Association (AHA) 6, 8

Lifestyle Modifications

• Smoking cessation is mandatory, and weight management targeting a healthy BMI is recommended, according to the American College of Cardiology (ACC) 6, 8
• Limit alcohol intake, as recommended by the National Kidney Foundation (NKF) 7

Monitoring Schedule

• Regular reassessment every 3-6 months includes eGFR, electrolytes, urine albumin-to-creatinine ratio, hemoglobin, and blood pressure, as recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) guideline 6

Critical Medications to Avoid

• NSAIDs (ibuprofen/Advil, naproxen/Aleve, ketorolac/Toradol) are absolute contraindications in CKD, as they cause acute kidney injury and accelerate progression, according to the American College of Rheumatology (ACR) 7

Evidence‑Based Pharmacologic and Multidisciplinary Management of Chronic Kidney Disease (Non‑Transplant)

First‑Line Disease‑Modifying Therapy

• Initiate an SGLT2 inhibitor (e.g., dapagliflozin 10 mg daily) as first‑line treatment for all patients with chronic kidney disease (CKD) whose estimated glomerular filtration rate (eGFR) is ≥ 20 mL/min/1.73 m², regardless of diabetes status; randomized controlled trials show a 39 % relative reduction in progression to end‑stage kidney disease or cardiovascular death (high‑quality evidence) [9][10].

Renin‑Angiotensin System (RAS) Inhibition

• Prescribe an ACE inhibitor or an angiotensin‑II receptor blocker at the maximally tolerated dose for patients with albuminuria or hypertension; this strategy is the cornerstone of renal protection (moderate evidence) 11.

Non‑Steroidal Mineralocorticoid Receptor Antagonist (MRA)

• Add finerenone to patients already receiving an SGLT2 inhibitor and a RAS blocker, especially those with high albuminuria, to obtain additional renal and cardiovascular protection (based on large RCTs, high‑quality evidence) [10][11].

GLP‑1 Receptor Agonist (Adjunctive Therapy)

• In adults with type 2 diabetes and CKD, GLP‑1 receptor agonists lower the risk of kidney function decline and kidney‑related mortality (moderate‑to‑high evidence) [9][10].

Combination Therapy Strategy

• Start simultaneous combination therapy with an SGLT2 inhibitor, a maximally dosed RAS blocker, and a statin; this “triple‑pill” regimen provides the core renal‑cardiovascular protective effect (moderate evidence) 11.
• The absolute benefit of the combination is greatest in patients with high albuminuria (UACR > 200 mg/g) (moderate evidence) 11.
• Perform systematic medication review and risk reassessment every 3–6 months to maintain optimal benefit‑risk balance (moderate evidence) 11.

Novel Biomarkers and Diagnostic Tools

• Use cystatin C‑based eGFR equations (race‑free) for more accurate assessment of kidney function (moderate evidence) [9][10].
• Measure urine albumin‑to‑creatinine ratio (UACR) as a mandatory diagnostic and monitoring parameter for CKD (high evidence) [9][10].
• Emerging urinary biomarkers—epidermal growth factor (uEGF), MCP‑1, and TIMP‑1—show promise for predicting disease progression (early‑phase evidence) 12.

Digital & Pharmacist‑Led Medication Safety

• Implement computerized prescribing alerts combined with clinical pharmacist support to reduce medication errors and inappropriate prescriptions in CKD (low‑to‑moderate evidence) [13][14].

Behavioral & Lifestyle Interventions

• Plant‑based dietary patterns, sodium restriction, and protein intake of ~0.8 g/kg body weight are associated with better blood‑pressure control and slower CKD progression (moderate evidence) 13.
• Structured physical‑activity programs and weight‑management counseling improve cardiovascular risk profiles (moderate evidence) 13.
• Cognitive‑behavioral therapy, peer support, mindfulness, and meditation provide psychosocial benefits without drug interactions (low‑to‑moderate evidence) [13][15]14.

Deprescribing & Pill‑Burden Reduction

• Systematic deprescribing—removing drugs with limited benefit or high risk based on age and renal function—reduces pill burden, improves patient satisfaction, and lowers mortality in older CKD cohorts (moderate evidence) [13][15]14.
• Fixed‑dose combination “polypill” formulations that include an SGLT2 inhibitor, RAS blocker, and statin may further simplify regimens (low‑to‑moderate evidence) [13][15]14.

Advanced Molecular Profiling & Artificial Intelligence

• Multi‑omics profiling (genomics, transcriptomics, proteomics, metabolomics) can identify CKD sub‑phenotypes and critical pathogenic pathways (early‑phase evidence) 12.
• AI algorithms that integrate biomarkers, imaging, and biopsy data are being developed to personalize prognosis and therapeutic decisions (early‑phase evidence) 12.
• International collaborative projects such as the BEAt‑DKD kidney atlas provide reference datasets to accelerate research and precision medicine (early‑phase evidence) 12.